<DOC>
	<DOCNO>NCT01030653</DOCNO>
	<brief_summary>Obese subject may require high fixed oral maintenance dose regimen voriconazole compare normal weight subject achieve comparable plasma exposure . The current study design address issue .</brief_summary>
	<brief_title>Pharmacokinetics Voriconazole Obese Subjects</brief_title>
	<detailed_description>The prevalence obesity increase tremendously past two decade . An estimated 1 5 person United States classify obese . Under representation obese patient pharmacokinetic trial grossly limit generalizability drug dose recommendation emerge population . No publish pharmacokinetic study voriconazole dose patient obesity currently exist literature . Specifically , voriconazole pharmacokinetic data subject body mass index ( BMI ) ≥ 35 kg/m2 ( Class II III obesity ) limit . Voriconazole available intravenous oral formulation . Anecdotal experience suggest use oral voriconazole significantly prevalent intravenous therapy . The current oral recommend dose regimen voriconazole include use 200 mg every 12 hour patient 40 kg . The dosage increase 300 mg mouth every 12 hour situation sufficient clinical response note . A weight base dose strategy also utilized patient serious infection ( 3-6 mg/kg IV Q 12 hour ) invasive aspergillosis . Voriconazole demonstrate non-linear pharmacokinetics dose base total body weight may result non-dose proportional exposure . For example , 1.5 fold dose increment voriconazole 200 mg 300 mg every 12 hour result 2.5 fold increase exposure . The appropriate body size descriptor unknown ( i.e . ideal body weight , fat free weight , lean body weight , etc . ) antimicrobial , include voriconazole . As consequence , appropriateness weight-based voriconazole dosage selection obese patient know . Intuitively , weight base dosing ( total body weight ) population could lead high expect exposure ( non-linear pharmacokinetics ) lead potential adverse event . Therapeutic drug monitoring increasingly advocated system improve voriconazole dosing . However , assay measure voriconazole concentration clinic routinely available . Hence , current pilot study propose characterize pharmacokinetic profile voriconazole obese subject use two fix dose regimen .</detailed_description>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>1. male female , 18 50 year age ; 2. nonsmoking lightsmoking ( ≤5 cigarette per day ) volunteer ; 3 . BMI ≥ 35 kg/m2 ; 4. female subject childbearing potential either surgically sterilize , use effective method contraception ( diaphragm , cervical cap , condom ) agree abstain sex time prestudy screening , entire study period 1 week follow study period . 1 . History significant hypersensitivity reaction intolerance voriconazole , fluconazole , itraconazole , posaconazole , ketoconazole ; 2. history significant clinical illness require pharmacological management ; 3. abnormal serum electrolyte complete blood count require clinical workup ; 4. transaminase ( AST ALT ) &gt; 2.5 x upper limit normal ; 5. estimate creatinine clearance &lt; 50 mL/min ( CockcroftGault equation ) ; 6. positive urine pregnancy test ( female ) ; 7. abnormal electrocardiogram ( ECG ) judge study physician ; 8. unable tolerate venipuncture multiple blood draw ; 9. clinically significant abnormal physical examination define physical finding require clinical workup .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Voriconazole</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Obese</keyword>
	<keyword>Healthy Volunteer</keyword>
</DOC>